Search Results for "bismuth subsalicylate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for bismuth subsalicylate. Results 1 to 3 of 3 total matches.
See also: Helidac, PeptoBismol

Two Vonoprazan Combinations (Voquezna) for H. pylori

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
. 5. Approximate WAC for 14 days of treatment using separate generic products (bismuth subsalicylate ...
The FDA has approved vonoprazan, a potassium-competitive acid blocker, copackaged with amoxicillin (Voquezna Dual Pak – Phathom) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults. Vonoprazan is the first potassium-competitive acid blocker to be approved in the US. It has been available in Japan for treatment of various acid-related disorders since 2014. Vonoprazan is not available alone in the US.
Med Lett Drugs Ther. 2022 Oct 31;64(1662):169-72 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
for treatment of H. pylori are diarrhea, nausea, vomiting, anorexia, and abdominal pain. Bismuth subsalicylate ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Talicia - A 3-Drug Combination for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
antibacterials Bismuth subsalicylate clarithromycin Helicobacter pylori infection levofloxacin metronidazole ...
The FDA has approved a fixed-dose combination of omeprazole, amoxicillin, and rifabutin (Talicia – RedHill) for treatment of Helicobacter pylori infection in adults. Talicia is the first rifabutin-based product to be approved for this indication.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-5 |  Show IntroductionHide Introduction